Refractory Metastatic Colorectal Cancer: Current Challenges and Future Prospects by Lam M, Lum C, Latham S, Tipping Smith S, Prenen H, Segelov E

Get full text

The Role of Neoadjuvant Chemotherapy in Locally Advanced Colon Cancer by Body A, Prenen H, Latham S, Lam M, Tipping-Smith S, Raghunath A, Segelov E

Get full text

CAPECITABINE (CAPE) +/- BEVACIZUMAB (BEV) IN THE ADJUVANT TREATMENT OF COLORECTAL CANCER (CRC) FIRST AND FINAL TOXICITY RESULTS FROM THE INTERNATIONAL PHASE III QUASAR2 TRIAL by Midgley, R, Love, S, Potter, V, Segelov, E, Ferry, DR, Weaver, A, Scudder, C, Julier, P, Grumett, S, Kerr, D

Cost-effectiveness of aspirin adjuvant therapy in early stage colorectal cancer in older patients by Soon, S, Chia, W, Chan, M, Ho, G, Jian, X, Deng, Y, Tan, C, Sharma, A, Segelov, E, Mehta, S, Ali, R, Toh, H, Wee, H

Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trial by Kerr, R, Love, S, Segelov, E, Johnstone, E, Falcon, B, Hewett, P, Weaver, A, Church, D, Scudder, C, Pearson, S, Julier, P, Pezzella, F, Tomlinson, I, Domingo, E, Kerr, D

Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trial by Love, S, Kerr, R, Segelov, E, Johnstone, E, Falcon, B, Hewett, P, Weaver, A, Church, D, Scudder, C, Pearson, S, Julier, P, Pezzella, F, Tomlinson, I, Domingo, E, Kerr, D